tiprankstipranks
Hutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel
PremiumThe FlyHutchmed withdraws NDA in China for fruquintinib in combination with paclitaxel
3M ago
Hutchmed reiterates 2024 guidance for Oncology/Immunology revenue $300M-$400M
Premium
The Fly
Hutchmed reiterates 2024 guidance for Oncology/Immunology revenue $300M-$400M
4M ago
Hutchmed reports 1H revenue $305.7M vs. $532.9M last year
Premium
The Fly
Hutchmed reports 1H revenue $305.7M vs. $532.9M last year
4M ago
Hutchmed chairman Simon To retires, Dan Eldar to succeed
PremiumThe FlyHutchmed chairman Simon To retires, Dan Eldar to succeed
6M ago
Hutchmed initiated with a Buy at Bocom
Premium
The Fly
Hutchmed initiated with a Buy at Bocom
6M ago
HUTCHMED Launches Innovative Cancer Treatment Trial
Premium
Company Announcements
HUTCHMED Launches Innovative Cancer Treatment Trial
6M ago
Hutchmed announces positive CHMP opinion for fruquintinib
PremiumThe FlyHutchmed announces positive CHMP opinion for fruquintinib
7M ago
HUTCHMED Announces Key Managerial LTIP Vesting
Premium
Company Announcements
HUTCHMED Announces Key Managerial LTIP Vesting
7M ago
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
Premium
Company Announcements
HUTCHMED to Unveil New Cancer Drug Data at AACR 2024
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100